Loading…
FUZATAL XL is a brand name for Alfuzosin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Treatment of the functional symptoms of benign prostatic hyperplasia (BPH).
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults The recommended dose is one 10 mg tablet daily to be taken after a meal. Renal impairment In patients with mild to moderate renal impairment (creatinine clearance > 30 ml/min), it is recommended to start treatment with a lower dose, to be increased to 10 mg depending on clinical response.
4). Hepatic impairment In patients with mild to moderate hepatic impairment, it is recommended not to use Alfuzosin 10 mg prolonged release tablets. After careful medical consideration, a preparation containing a lower dose of alfuzosin hydrochloride might be considered appropriate.
3). Alfuzosin 10 mg prolonged release tablets must not be divided to achieve lower dose in patients with mild to moderate hepatic impairment. Preparations containing a lower dosage should be used. Refer to the corresponding product information for dosing instructions.
There is no relevant indication for use of Alfuzosine 10 mg prolonged release tablets in children. Method of administration Oral adminstration. g. a glass of water). 4). The first dose should be taken at bedtime. The prolonged-release tablet 10 mg should be taken immediately after the same meal each day.
The adverse reactions considered at least possibly related to treatment are listed below by body system organ class and absolute frequency. Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10 000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
4) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The patient should be examined before commencement of therapy with alfuzosin to exclude the presence of other conditions that can produce similar symptoms to those of BPH. - Alfuzosin 10 mg should not be administered to patients with severely impaired renal function (creatinine clearance < 30 ml/min) as there are no clinical safety data available for this patient group.
- Alfuzosin should be given with caution to patients treated with antihypertensive medicinal products or nitrates. Blood pressure should be monitored regularly, especially at the beginning of treatment. - In some subjects postural hypotension may develop, with or without symptoms (dizziness, fatigue, sweating) within a few hours following administration.
These effects are usually transient occur at the beginning of treatment and do not usually prevent the continuation of treatment. In such cases, the patient should lie down until the symptoms have completely disappeared. Pronounced drop in blood pressure has been reported in post-marketing surveillance in patients with pre-existing risk factors (such as underlying cardiac diseases and/or concomitant treatment with anti-hypertensive medication).
8). Caution should be exercised when prescribing alfuzosin to elderly patients. The patient should be warned of the possible occurrence of such events. - Caution should be exercised when alfuzosin is administered to patients who have responded with pronounced hypotension to other alpha1-blockers.
- Treatment should be initiated gradually in patients with hypersensitivity to other α1-receptor blockers. - As with all α1-receptor blockers, alfuzosin should be used with caution in patients with acute cardiac failure. - In cardiac patients the treatment of coronary insufficiency should continue taking into account that the concomitant administration of nitrates and alfuzosin may increase the risk of occurrence of hypotension.
g. 5).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Alfuzosin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Alfuzosin should be discontinued if angina pectoris recurs or worsens. - Patients with congenital QTc prolongation, a known history of acquired QTc prolongation or who are taking medicinal products known to increase the QTc interval should be evaluated before and during the administration of alfuzosin.
- The ‘Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded.
As IFIS may lead to increased procedural complications during the cataract operation current or past use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery, even though the risk of this event with alfuzosin appears to be very low.
- Patients should be instructed to swallow the tablets whole. Other methods of administration such as crunching, crushing, grinding, pounding or chewing the tablet should be avoided. Incorrect administration may lead to undesirable release and absorption of the active substance, with a risk of early undesirable effects.
Excipient(s) Lactose This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.